首页|基于ORAI1/NFAT信号轴探讨镇心安神方对1-氯-2,4-二硝基苯诱导特应性皮炎小鼠的作用及机制

基于ORAI1/NFAT信号轴探讨镇心安神方对1-氯-2,4-二硝基苯诱导特应性皮炎小鼠的作用及机制

扫码查看
目的 基于钙通道调节分子 1(ORAI1)/T细胞核因子(NFAT)信号轴探讨镇心安神方(龙骨、牡蛎、淡竹叶、骨碎补、茯苓)对特应性皮炎(AD)小鼠的作用及机制.方法 将 36 只BALB/c小鼠随机分为空白对照组、模型组、西替利嗪组(1.3 mg·kg-1)及镇心安神方组(36.36 g·kg-1),每组 9 只.采用 1-氯-2,4-二硝基苯(DNCB)诱导建立AD小鼠模型.灌胃给药,每日 1 次,连续给药 2 周.给药结束后,测定皮损面积,并对皮损严重程度进行评分;测定脾脏质量,计算脾脏指数;采用HE染色法观察皮损组织病理变化;ELISA法检测血清中白细胞介素 4(IL-4)、IL-13 及胸腺基质淋巴细胞生成素(TSLP)的含量;Western Blot法检测皮损组织中ORAI1、钙调磷酸酶A(CaN)、T细胞核因子 2(NFAT2)蛋白表达水平.结果 与空白对照组比较,模型组小鼠的皮损评分显著升高(P<0.01),皮损面积显著扩大(P<0.01);表皮层及真皮层厚度显著增加(P<0.01),表皮过度角化,棘层肥厚,真皮层可见嗜酸性粒细胞、淋巴细胞等炎性细胞浸润;脾脏指数及血清IL-4、IL-13、TSLP水平显著升高(P<0.01);皮损组织中CaN、NFAT2、ORAI1 蛋白表达水平显著升高(P<0.01).与模型组比较,镇心安神方组小鼠的皮损评分显著降低(P<0.01),皮损面积显著缩小(P<0.01);表皮层及真皮层厚度显著降低(P<0.01),表皮过度角化减轻,棘层轻度肥厚,真皮层有少量炎性细胞浸润;脾脏指数及血清IL-4、IL-13、TSLP水平显著降低(P<0.01);皮损组织中CaN、NFAT2、ORAI1 蛋白表达水平显著降低(P<0.01).结论 镇心安神方能够改善DNCB诱导AD小鼠的皮肤病理损伤,可能与其抑制ORAI1、CaN及NFAT2 蛋白表达,降低血清TSLP、IL-4、IL-13 等 2 型炎症因子水平,通过免疫调节改善皮肤炎症及瘙痒有关.
Effects and Mechanisms of Zhenxin Anshen Prescription on 1-Chloro-2,4-Dinitrobenzene-Induced Atopic Dermatitis Mice Based on ORAI1/NFAT Signaling Asix
Objective To investigate the effects and mechanisms of Zhenxin Anshen Prescription(composed of Os Draconis,Ostreae Concha,Lophatheri Herba,Drynariae Rhizoma,Poria)on mice with atopic dermatitis(AD)based on the calcium channel regulator 1(ORAI1)/nuclear factor of T-cells(NFAT)signalling axis.Methods Thirty-six BALB/c mice were randomly divided into a blank control group,a model group,a Cetirizine group(1.3 mg·kg-1)and a Zhenxin Anshen Prescription group(36.36 g·kg-1),with nine mice in each group.AD mouse model was established using 1-chloro-2,4-dinitrobenzene(DNCB)induction.The drug was administered by gavage once a day for 2 weeks.At the end of drug administration,the area of skin lesions was measured and the severity of skin lesions was scored;spleen mass was measured and spleen index was calculated;pathological changes of skin lesion tissues were observed by HE staining;interleukin 4(IL-4),IL-13 and thymic stromal lymphopoietin(TSLP)in serum were detected by ELISA;and the protein expression levels of ORAI1,calmodulin phosphatase A(CaN)and nuclear factor of T cells 2(NFAT2)were detected by Western Blot.Results Compared with the blank control group,the skin lesion score of mice in the model group was significantly increased(P<0.01),the skin lesion area was significantly enlarged(P<0.01);the thickness of the epidermis and dermis were significantly increased(P<0.01),hyperkeratosis of the epidermis,hypertrophy of the stratum spinosum,and infiltration of inflammatory cells such as eosinophils and lymphocytes can be seen in the dermis;the splenic index and serum IL-4,IL-13,TSLP levels were significantly increased(P<0.01);protein expression levels of CaN,NFAT2,ORAI1 were significantly increased in the skin lesion tissues(P<0.01).Compared with the model group,the dermatitis score of mice in the Zhenxin Anshen Prescription group was significantly decreased(P<0.01),the lesion area was significantly reduced(P<0.01),the epidermal and dermal thicknesses(P<0.01),the hyperkeratosis of epidermis was alleviated,the spinous layer was slightly hypertrophic,and there was a small amount of inflammatory cell infiltration in the dermis;the splenic index and the levels of serum IL-4,IL-13,and TSLP were significantly decreased(P<0.01);the protein expressions levels of CaN,NFAT2,and ORAI1 in the skin lesion tissues were significantly decreased(P<0.01).Conclusion Zhenxin Anshen Prescription can ameliorate dermatopathological injury in DNCB-induced AD mice,and the mechanism may be related to its ability to inhibit the protein expressions of ORAI1,CaN and NFAT2,reduce the levels of serum type 2 inflammatory factors TSLP,IL-4 and IL-13,and ameliorate cutaneous inflammation and itching through immunomodulation.

Zhenxin Anshen Prescriptionatopic dermatitisORAI1/NFAT signaling asiximmunomodulatorymice

陈若曦、姜姗姗、杨洁、杨晓宇、徐蕊瑶、方琳、赵一丁

展开 >

陕西中医药大学,陕西 咸阳 712046

陕西省中医药研究院,陕西 西安 710003

陕西省中医医院,陕西 西安 710003

镇心安神方 特应性皮炎 ORAI1/NFAT信号轴 免疫调节 小鼠

国家自然科学基金项目国家自然科学基金项目陕西省中医药管理局科研项目

81704087822745372021-GJ-JC010

2024

中药新药与临床药理
广州中医药大学

中药新药与临床药理

CSTPCD北大核心
影响因子:0.908
ISSN:1003-9783
年,卷(期):2024.35(2)
  • 19